MX2017002453A - Neprilisina como marcador pronostico de insuficiencia cardiaca. - Google Patents
Neprilisina como marcador pronostico de insuficiencia cardiaca.Info
- Publication number
- MX2017002453A MX2017002453A MX2017002453A MX2017002453A MX2017002453A MX 2017002453 A MX2017002453 A MX 2017002453A MX 2017002453 A MX2017002453 A MX 2017002453A MX 2017002453 A MX2017002453 A MX 2017002453A MX 2017002453 A MX2017002453 A MX 2017002453A
- Authority
- MX
- Mexico
- Prior art keywords
- heart failure
- neprilysin
- prognostic marker
- failure prognostic
- determining
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
- G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
- G01N2333/96497—Enkephalinase (3.4.24.11)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14182846.7A EP2990800A1 (en) | 2014-08-29 | 2014-08-29 | Neprilysin as heartfailure (HF) prognostic marker |
| PCT/EP2015/068729 WO2016030209A1 (en) | 2014-08-29 | 2015-08-14 | Neprilysin as heart failure prognostic marker |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017002453A true MX2017002453A (es) | 2017-10-23 |
Family
ID=51421966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017002453A MX2017002453A (es) | 2014-08-29 | 2015-08-14 | Neprilisina como marcador pronostico de insuficiencia cardiaca. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10203341B2 (https=) |
| EP (2) | EP2990800A1 (https=) |
| JP (1) | JP6661216B2 (https=) |
| CN (1) | CN107076758B (https=) |
| AU (1) | AU2015309112A1 (https=) |
| CA (1) | CA2959094A1 (https=) |
| ES (1) | ES2734876T3 (https=) |
| MX (1) | MX2017002453A (https=) |
| RU (1) | RU2017109086A (https=) |
| SG (1) | SG11201701393YA (https=) |
| WO (1) | WO2016030209A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7510649B2 (ja) | 2019-11-06 | 2024-07-04 | 国立大学法人 香川大学 | 心不全マーカー |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ565994A (en) * | 2001-09-03 | 2010-02-26 | Intreat Pty Ltd | Antibodies to non-functional P2X7 receptor, diagnosis and treatment of cancers and other conditions |
| AU2010315008B2 (en) * | 2009-11-07 | 2015-12-03 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| EP2360280A1 (en) * | 2010-02-24 | 2011-08-24 | Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol | Genetic marker for the diagnosis of dementia with Lewy bodies |
| WO2012106152A1 (en) * | 2011-02-03 | 2012-08-09 | Abbott Laboratories | Methods of prognosis and diagnosis in chronic heart failure |
| EP2836841B1 (en) * | 2012-04-12 | 2022-01-05 | B.R.A.H.M.S GmbH | Prognosis of adverse events in patients with suspected chronic heart failure |
| ES2879550T3 (es) * | 2012-08-24 | 2021-11-22 | Novartis Ag | Inhibidores de epn para tratar enfermedades caracterizadas por la dilatación o remodelación auriculares. |
| US20140206632A1 (en) | 2013-01-22 | 2014-07-24 | Singulex, Inc. | Endothelin in the Diagnosis of Cardiac Disease |
| US9102635B2 (en) * | 2013-02-14 | 2015-08-11 | Novartis Ag | Substituted bisphenyl butanoic acid derivatives as NEP inhibitors with improved in vivo efficacy |
| CU24330B1 (es) * | 2013-02-14 | 2018-03-13 | Novartis Ag | Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral) |
-
2014
- 2014-08-29 EP EP14182846.7A patent/EP2990800A1/en not_active Withdrawn
-
2015
- 2015-08-14 US US15/506,665 patent/US10203341B2/en not_active Expired - Fee Related
- 2015-08-14 MX MX2017002453A patent/MX2017002453A/es unknown
- 2015-08-14 WO PCT/EP2015/068729 patent/WO2016030209A1/en not_active Ceased
- 2015-08-14 SG SG11201701393YA patent/SG11201701393YA/en unknown
- 2015-08-14 CA CA2959094A patent/CA2959094A1/en not_active Abandoned
- 2015-08-14 AU AU2015309112A patent/AU2015309112A1/en not_active Abandoned
- 2015-08-14 JP JP2017511945A patent/JP6661216B2/ja not_active Expired - Fee Related
- 2015-08-14 CN CN201580050585.0A patent/CN107076758B/zh not_active Expired - Fee Related
- 2015-08-14 EP EP15750737.7A patent/EP3186639B1/en not_active Not-in-force
- 2015-08-14 RU RU2017109086A patent/RU2017109086A/ru not_active Application Discontinuation
- 2015-08-14 ES ES15750737T patent/ES2734876T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2734876T3 (es) | 2019-12-12 |
| EP3186639B1 (en) | 2019-03-20 |
| JP6661216B2 (ja) | 2020-03-11 |
| CA2959094A1 (en) | 2016-03-03 |
| RU2017109086A3 (https=) | 2019-03-06 |
| WO2016030209A1 (en) | 2016-03-03 |
| JP2017526924A (ja) | 2017-09-14 |
| US20170254815A1 (en) | 2017-09-07 |
| US10203341B2 (en) | 2019-02-12 |
| EP2990800A1 (en) | 2016-03-02 |
| AU2015309112A1 (en) | 2017-04-06 |
| SG11201701393YA (en) | 2017-03-30 |
| CN107076758A (zh) | 2017-08-18 |
| RU2017109086A (ru) | 2018-10-01 |
| EP3186639A1 (en) | 2017-07-05 |
| CN107076758B (zh) | 2019-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3757225A3 (en) | Pancreatic cancer detection kit or device, and detection method | |
| EP4060048A3 (en) | Non-invasive diagnostic method for diagnosing bladder cancer | |
| EP3816303A3 (en) | Breast cancer detection kit or device, and method for detecting breast cancer | |
| EP4464797A3 (en) | Kit, device, and method for detecting lung cancer | |
| EA201590027A1 (ru) | Способы детекции заболеваний или состояний | |
| EP4461824A3 (en) | Detection kit or device and detection method for biliary tract cancer | |
| WO2014201516A3 (en) | Biomarker identification | |
| BR112018069849A2 (pt) | kit, dispositivo e método para a detecção de câncer pancreático precoce ou de lesão precursora do câncer pancreático | |
| BR112012030587A2 (pt) | métodos para diagnóstico de câncer pancreático, para identificar se um indivíduo precisa ou não de uma terapia contra câncer pancreático e para determinar se uma terapia contra câncer pancreático obtém sucesso, dispositivo para diagnóstico de câncer pancreático e uso de pelo menos um biomarcador | |
| MX2016012285A (es) | Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf. | |
| EP4202441A3 (en) | Gene expression profile in macrophages for the diagnosis of cancer | |
| EA201790769A1 (ru) | Определение уровней гликозаминогликанов методом масс-спектрометрии | |
| MX2017003370A (es) | Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica. | |
| MX358474B (es) | Biomarcadores salivales específicos para detección de riesgo, diagnóstico temprano, pronóstico y vigilancia de las enfermedades de alzheimer y de parkinson. | |
| EP4513187A3 (en) | Methods of detecting prostate cancer | |
| WO2015077382A3 (en) | Combined cytology and molecular testing for early detection of esophageal adenocarcinoma | |
| EP3438277A4 (en) | PROCESS FOR DETERMINING WHETHER A TEST PROCEDURE CONTAINS PHYTOPATHOGENIC MUSHROOMS OR NOT | |
| MX2019002818A (es) | Metodos para detectar anticuerpos neutralizantes anti-leptina. | |
| EP4428251A3 (en) | Methods of detecting prostate cancer | |
| MX382809B (es) | Uso de tm9sf4 como un biomarcador para exosomas asociadas con tumores. | |
| GB2552271A (en) | A method for diagnosing lung cancer | |
| EP3206032A4 (en) | Method for detecting cardiac failure patient, method for discrimination of cardiac disease, test reagent for cardiac failure, test kit for cardiac failure, device for detecting cardiac failure, and program for detecting cardiac failure | |
| MX2015015015A (es) | Metodo para diagnosticar cancer. | |
| MX384636B (es) | Método para detectar anticuerpos neutralizantes contra la insulina humana recombinante en suero humano. | |
| GB201114909D0 (en) | Biomarkers for lysosomal storage disorders |